 I. To determine the effectiveness of these combinatorial therapies by assessing NY-ESO-1 specific cellular and humoral immunity: peripheral blood NY-ESO-1 specific cluster of differentiation CD8 and CD4 T-cells; peripheral blood NY-ESO-1 specific antibodies; peripheral blood frequency of CD4 CD25 forkhead box P3 FOXP3 regulatory T-cells; explore time to disease progression. 